Susanne Posel, Contributor

Activist Post

The Food and Drug Administration (FDA) has given GlaxoSmithKilne (GSK) their approval of the MenHibrix vaccine(MHV), which is meant for infants between the ages of 6 weeks to 18 months. This vaccine is a dangerous mixture of the meningococcal disease and Hib disease.

MHV will be manufactured in Rixensart, a Belgium-based arm of GSK Biologicals.

In 2010 and 2011, the FDA rejected MHV. GSK claims that they have “resolved” the FDA’s concerns about the necessity, potency and efficiency of MHV. This simply accepted GSK’s word that they have taken care of the vaccine’s issues. The FDA does not require more proof than that.

In fact, the FDA’s standard practice is to regulate drugs after they have been approved, rather than just making sure they are safe before releasing them out to the public.

In 2008, the FDA admitted that there is no regulatory checking of safety of trials. The FDA relied solely on the data provided them from the drug makers themselves.

Furthermore, the FDA does not check or regulate cosmetics prior to their release to the markets for the public to purchase. They leave the safety responsibility to the cosmetic corporations to essentially regulate themselves.

According to the Centers for Disease Control and Prevention (CDC), infants are most at risk for contracting bacterial meningitis, which is an infection that attacks the thin lining surrounding the brain and spinal cord.

Last month, the CDC was involved in a propaganda campaign to coerce Americans to start receiving immunizations after the recent decline reported by doctors across the country.

Karen Midthum, director of the center for biologics at the FDA stated that:

With today’s approval of Menhibrix, there is now a combination vaccine that can be used to prevent potentially life-threatening Hib disease and two types of meningococcal disease in children. It is the first meningococcal vaccine that can be given starting as young as six weeks of age.

The MHV will be administered as a four-dose vaccine that the CDC recommended is added to infant’s immunizations schedule.

Dr. Leo Friedland, vice president of clinical and medical affairs at GSK North American division says:

(Meningitis) is one of those diseases that although not common, when it occurs it’s absolutely devastating and horrible. It presents to the doctor when a child just looks ill, and within 18 to 24 hours, they’re on the deathbed in the hospital. . . To be able to have a vaccine to prevent meningitis is really a great day.

The MHV targets only the C and Y strains of meningococcal bacteria and the Hib bacteria (a.k.a. Haemophilus influenzae type b).

GSK says there is no vaccine in the US to treat the B strain of the meningococcal bacteria.

GSK is planning on administering 1.1 billion doses of MHV to 173 countries in developed and developing countries.

GSK maintains that MHV was evaluated on 7,500 infants and toddlers in the U.S., Mexico and Austria.

Pfizer, one of GSK’s biggest competitors, was part of a campaign in Southern Africa and India where they were conducting experiments with their meningitis vaccine on underdeveloped children in nations where their access to healthcare is severely limited.

This experiment was perfectly timed. While a meningitis epidemic broke out in Nigeria, Pfizer happen to coincide this problem with the reveal of Trovan, which was distributed to Nigerians in response to the “outbreak”.

To receive the Food and Drug Administration’s certification of approval, Pfizer used Africa as their clinical trial laboratory to produce the proof they needed to make Trovan a profitable endeavor.

The St. Louis University’s (SLU) Center for Vaccine Development (CVD) is conducting a study with Pfizer, to create a vaccine for meningitis specifically targeting children.

Dr. Edwin Anderson, researcher at SLU’s CVD states:

An effective adolescent vaccine against meningococcal B disease has the potential to help save lives and reduce emotional and psychological stress caused by long-term consequences of the disease.

This vaccine will target the human immune system, our body’s natural defense against disease. Their purpose is to find an effective way of tricking the human immune system. Traditional use of dead cultures in this instance is ineffective, says Anderson.

Because of the adverse reactions, the use of live cultures of dangerous diseases and the proven ineffectual nature of vaccines, this rush to find a meningitis vaccine targeting our children is simply another attempt by Big Pharma to undermine our natural ability to remain healthy.

Susanne Posel is the Chief Editor of Occupy Corporatism. Our alternative news site is dedicated to reporting the news as it actually happens; not as it is spun by the corporately funded mainstream media. You can find us on our Facebook page.